US Appeals Court Rules For Sanofi In Eloxatin Patent Case
10 Septembre 2009 - 6:25PM
Dow Jones News
A federal appeals court ruled for Sanofi-Aventis SA (SNY)
Thursday in a patent fight with generic drug companies that want to
offer competing versions of Sanofi's colon cancer drug
Eloxatin.
The U.S. Court of Appeals for the Federal Circuit threw out a
trial court ruling in favor of the generic competitors, saying the
trial judge misconstrued Sanofi's patent claims.
The appeals court sent the case back for further
proceedings.
Teva Pharmaceutical Industries Ltd. (TEVA), Hospira Inc.(HSP)
and Novartis AG's (NVS) Sandoz unit are among those seeking to
offer generic versions of the Sanofi drug.
-By Brent Kendall, Dow Jones Newswires; 202-862-9222;
brent.kendall@dowjones.com